Prosecution Insights
Last updated: November 04, 2026
Application No. 18/688,269

METHODS AND MATERIALS TO TREAT NEURODEGENERATIVE DISEASE

Non-Final OA §112
Filed
Feb 29, 2024
Priority
Aug 30, 2021 — provisional 63/238,252 +4 more
Examiner
ABBAS, SYED JARAR
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Abyssinia Biologics Inc.
OA Round
1 (Non-Final)
25%
Grant Probability
At Risk
1-2
OA Rounds
9m
Est. Remaining
25%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
1 granted / 4 resolved
-35.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
35 currently pending
Career history
43
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
19.7%
-20.3% vs TC avg
§102
25.2%
-14.8% vs TC avg
§112
36.7%
-3.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 4 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I (claim(s) 8-11, 13-15 and 17 drawn to a method for detecting oA3 in a sample comprising one or more biological fluids, preferably a sample from a human subject, the method comprising: contacting the sample with capture antibodies bound to a surface, wherein the capture antibodies comprise an antibody or antigen-binding fragment of claim 30 contacting the sample with a labeled detection antibody comprising a detectable label, wherein the detection antibody binds to the capture antibody-oA3 complexes, under conditions sufficient for the detection antibody to bind to the capture antibody-oA3 complexes; and detecting and optionally quantifying the detectable label, wherein the amount of detectable label is proportional to the amount of oA3 in the sample, thereby detecting oA3 in the sample) in the reply filed on 9/18/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). After further consideration, claims 30-32 have been rejoined with group I. Claims 1-4, 18-20, 23, 26-27, 29 and 33 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/18/26. 3. Claims 8-11, 13-15, 17 and 30-32 are under examination. Information Disclosure Statement The information disclosure statements (IDS) submitted 06/26/2023, 10/11/2024, and 3/18/2025 and the references cited therein have been considered, unless indicated otherwise. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Specification 6. The use of the term “Jitterbug” (page 73), which is a trade name or a mark used in commerce, has been noted in this application. The term should be accompanied by the generic terminology; furthermore the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. Please review the specification for other trademarks and appropriate correction is required. Claim Objections Claim 17 is objected to because of the following informalities: The phrase “a nucleic acid that labeled an antibody” appears to be a typographical error. The way it is read says the nucleic acid did the labeling. Amending the claims to recite “an immune-PCR assay comprising amplifying, by PCR, a nucleic acid label attached to the detected antibody and detecting the amplified nucleic acid”, would overcome the objection. The phrase “detecting turbidity occurred by forming an immunocomplex” appears to be a typographical error. The phrase “occurring by forming” is grammatically incorrect. Amending the claims to recite “a turbidimetric immunoassay method comprising detecting turbidity caused by formation of an immunocomplex”, would overcome the objection. Clarification and/or correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 7. Claims 8-11, 13-15 and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites “preferably a sample from a human subject.” A claim that sets out a broad limitation together with a narrower “preferred” limitation is indefinite. It is unclear whether the narrower limitation is required. See MPEP 2173.05(d). Claims 9, 11, 13-15, and 17 are included in this rejection because they depend from a rejected claim and do not cure the deficiencies of claim 8. 8. Claims 8-11, 13-15 and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 recites “the capture antibody-oAB complexes”. There is insufficient antecedent basis for this limitation. The claim never recites formation complexes between the capture antibodies and oAB, or condition under which oAB binds the capture antibodies. Dependent claims 9, 11, 13-15, 17 are included in this rejection because they do not cure the deficiencies of claim 8. 9. Claim 10 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 10 recites that the capture antibodies comprise “71A1 or 1G6 antibody or an antigen binding fragment thereof”. “71A1” or “1G6” are laboratory designations. They are arbitrary, do not convey the structure of the antibodies, and could be applied to different antibodies by others. The metes and bounds of the claim cannot be determined from the designations alone. It is also unclear whether “71A1” or “1G5” refer to the antibody of claim 30 or to some other antibody bearing those names. Clarification and/or correction is required. 11. Claim 17 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 17 recites “detecting and optionally quantifying the concentration of oAB in the sample”. There is insufficient antecedent basis for this limitation. Claim recites detecting and optionally quantifying “the detectably label”, not the concentration of oAB. 12. Claim 30-32 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 30 is indefinite for 2 reasons. The claim recites: (a) the VH domain comprises CDR-H1, CDR-H2, and CDR-H3 sequences from a VH domain sequence selected from the group consisting of SEQ ID NOs: 20-22 and a VL domain sequence selected from the group consisting of SEQ ID NOs:25-27; or (b) the VH domain comprises CDR-H1, CDR-H2, and CDR-H3 sequences from a VH domain sequence selected from the group consisting of SEQ ID NOs: 30-32 and a VL domain sequence selected from the group consisting of SEQ ID NOs:35-37. The first issue is that SEQ ID NO: 20-22 and 25-27 are CDR sequences. These are not “from a VH or VL sequence”. It is suggested that applicant amend the claim to recite: “(a) the VH domain comprises CDR-H1, CDR-H2, and CDR-H3 sequences selected from the group consisting of SEQ ID NOs: 20-22, respectively, and the VL domain comprises CDR-L1, CDR-L2, and CDR-L3 sequences selected from the group consisting of SEQ ID NOs:25-27, respectively; or (b) the VH domain comprises CDR-H1, CDR-H2, and CDR-H3 sequences selected from the group consisting of SEQ ID NOs: 30-32, respectively, and a VL domain comprises CDR-L1, CDR-L2, and CDR-L3 sequences selected from the group consisting of SEQ ID NOs:35-37. The second issue is SEQ ID NO: 26 and 36 refer to CDRs in the VL domain, however, there is no sequence that SEQ ID NO: 26 and 36 are attributed to. The applicant may write out the sequence to refer to those CDRs or attribute those CDRs to SEQ ID NOs that exist with an appropriate amino acid sequence. Claims 31 and 32 do not cure the deficiencies of claim 30, and thus are included in the rejection. Claim Status 12. No claims are allowed. Conclusion 13. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Savage, et al. (US Patent Application Publication 20140120037 A1, published May 1, 2014) teaches a method for detection of amyloid beta oligomers associated with Alzheimer’s disease in a biological sample. The invention also provides method for diagnosing and evaluating treatment for AD. Savage, et al. teach detection antibodies such as 19.3, 7305, 82E1, W02, and 6E10. However, the antibodies taught by the instant claims are 71A1 and 1G5 which VH domain of SEQ ID NO: 19 and VL domain of SEQ ID NO: 24 or VH domain SEQ ID NO: 29 and VL domain of SEQ ID NO: 34. The claimed antibody sequences are different from the detection antibodies taught in Savage, et al. 14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Syed J Abbas whose telephone number is (571)272-0015. The examiner can normally be reached M-Th, 9:00AM-4:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SYED J ABBAS/Examiner, Art Unit 1674 /VANESSA L. FORD/Supervisory Patent Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Feb 29, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
25%
Grant Probability
25%
With Interview (+0.0%)
3y 5m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 4 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month